KemPharm to Present at the 33rd Annual Roth Conference
05 March 2021 - 8:41AM
KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical
company focused on the discovery and development of proprietary
prodrugs, today announced that Travis C. Mickle, Ph.D.,
President and CEO of KemPharm, will present at the
33rd Annual Roth Conference being held virtually from March 15-17,
2021. The presentation will be available on demand during the
virtual event for all registered attendees.
Details regarding KemPharm’s presentations are
as follows:
Event: |
|
33rd Annual Roth
Conference |
Date: |
|
Monday, March 15, 2021 to
Wednesday, March 17, 2021 |
Time: |
|
Available on Demand |
Registration: |
|
https://roth.meetmax.com/sched/event_70981/conference_home.html |
During the pre-recorded virtual
presentation, Dr. Mickle will provide an overview
of KemPharm’s corporate achievements and potential milestones,
including the U.S. Food and Drug Administration’s (FDA) recent
approval of AZSTARYS™ (formerly known as KP415), a once-daily
product for the treatment of attention deficit hyperactivity
disorder (ADHD) in patients age six years and older. AZSTARYS
consists of serdexmethylphenidate (SDX), KemPharm’s prodrug of
d-methylphenidate (d-MPH), co-formulated with immediate-release
d-MPH.
The complete label for AZSTARYS, including
prescribing information and important safety information, may be
found at
https://kempharm.com/wp-content/uploads/2021/03/AZSTARYS-Master-Label-Final_20210302.pdf.
About KemPharm:
KemPharm is a specialty pharmaceutical company
focused on the discovery and development of proprietary prodrugs to
treat serious medical conditions through its proprietary LAT®
(Ligand Activated Therapy) technology. KemPharm utilizes its
proprietary LAT® technology to generate improved prodrug versions
of FDA-approved drugs as well as to generate prodrug versions of
existing compounds that may have applications for new disease
indications. KemPharm’s product portfolio is highlighted by
AZSTARYS™, an FDA-approved, once-daily treatment for attention
deficit hyperactivity disorder (ADHD) which is based on
serdexmethylphenidate, (SDX), KemPharm’s prodrug of
d-methylphenidate (d-MPH). KemPharm is also advancing several
clinical development candidates, including KP484 for the treatment
of ADHD and KP879 for the treatment of Stimulant Use Disorder
(SUD). AZSTARYS, KP484, and KP879 are all based on SDX. In
addition, KemPharm has received FDA approval for APADAZ®, an
immediate-release combination product containing benzhydrocodone, a
prodrug of hydrocodone, and acetaminophen. For more information on
KemPharm and its pipeline of prodrug product candidates visit
www.kempharm.com or connect with us on Twitter, LinkedIn, Facebook
and YouTube.
Caution Concerning Forward Looking
Statements:
This press release may contain forward-looking
statements made in reliance upon the safe harbor provisions of
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended.
Forward-looking statements include all statements that do not
relate solely to historical or current facts, including without
limitation KemPharm’s proposed development and commercial
timelines, and can be identified by the use of words such as “may,”
“will,” “expect,” “project,” “estimate,” “anticipate,” “plan,”
“believe,” “potential,” “should,” “continue” or the negative
versions of those words or other comparable words. Forward-looking
statements are not guarantees of future actions or performance.
These forward-looking statements include statements about the
commercial launch of AZSTARYS, including the timing of launch, the
regulatory milestone payment, and the potential clinical benefits
of AZSTARYS. These forward-looking statements are based on
information currently available to KemPharm and its current plans
or expectations and are subject to a number of uncertainties and
risks that could significantly affect current plans. Risks
concerning KemPharm’s business are described in detail in the “Risk
Factors” sections of KemPharm’s Annual Report on Form 10-K for the
year ended December 31, 2019, KemPharm’s Quarterly Report on Form
10-Q for the quarter ended September 30, 2020, and KemPharm’s other
filings with the Securities and Exchange Commission. KemPharm is
under no obligation to, and expressly disclaims any such obligation
to, update or alter its forward-looking statements, whether as a
result of new information, future events or otherwise.
KemPharm Contacts:
Tiberend Strategic Advisors, Inc.Jason
Rando/Maureen McEnroe, CFA(212) 375-2665 /
2664jrando@tiberend.commmcenroe@tiberend.com
KemPharm (NASDAQ:KMPH)
Historical Stock Chart
From Apr 2024 to May 2024
KemPharm (NASDAQ:KMPH)
Historical Stock Chart
From May 2023 to May 2024